PMR-116 / Pimera Therap - LARVOL DELTA

PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies (AACR 2026) - "First-generation Pol I inhibitor CX-5461 showed clinical benefits but also triggered non-specific DNA damage. No global DNA damage signalling was detected at active dose levels.Overall, PMR-116 shows potent anti-cancer activity across a wide range of malignancies, with particular strength in MYC-driven tumours. Its selectivity for Pol I and favourable safety profile support its progression into an MRFF-funded phase II basket trial commencing in 2026."

Clinical • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Hematological Malignancies • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor • MYC • NRAS • TP53

Targeting the nucleoli as a strategy to treat ovarian cancer (LCC 2026) - "Inhibitors of Pol I transcription CX-5461, BMH-21 and PMR116 have demonstrated therapeutic benefits in various preclinical cancer models and in Phase I clinical trials. Cyclin dependent kinases (CDKs), topoisomerases and novel compounds were identified as candidate hits that induce potent nucleolar stress. In summary, our work uncovered specific pathways/factors as mediators of nucleolar stress and potential cancer therapeutic targets."

Oncology • Ovarian Cancer • Solid Tumor

A novel ribosome biogenesis inhibitor, PMR-116, displays broad spectrum efficacy in preclinical tumour models (EACR 2025) - "PMR-116 significantly reduced cancer growth in a wide range of tumor models, including GEMM, syngeneic and PDX models. PMR-116 is undergoing clinical testing in phase I in solid tumors with the objective to determine maximum tolerated dose and identify a phase II dose."

Preclinical • Acute Myelogenous Leukemia • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor • NRAS • TP53

Pimera Therapeutics Announces Grant Award from Medical Research Future Fund (MRFF) for Expansion of Phase 1a/b Study of PMR-116 for MYC-driven Cancers (PRNewswire) - "Pimera Therapeutics, Inc...announced today a grant award from the Medical Research Future Fund (MRFF) that will enable the expansion of a Phase 1a/b study evaluating its lead program, PMR-116, for multiple difficult-to-treat cancer indications....PMR-116 has moved through dose escalation in the Phase 1a/b clinical trial, and with this new grant, the Company can expand the development of PMR-116 in patients with MYC overexpressing solid tumors in a tumor type-agnostic approach."

Financing • Breast Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor

PMR-116, a second generation RNA Polymerase I inhibitor (AACR 2024) - "PMR-116 significantly reduced cancer growth in a wide range of tumor models, including GEMM, syngeneic and PDX models. PMR-116 is undergoing clinical testing in phase I in solid tumors with the objective to determine maximum tolerated dose and identify a phase II dose."

Acute Myelogenous Leukemia • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor • NRAS • TP53

PMR-116, a second generation RNA Polymerase I inhibitor (EACR-AACR 2024) - "Conclusion PMR-116 significantly reduced cancer growth in a wide range of tumor models, including GEMM, syngeneic and PDX models. PMR-116 is undergoing clinical testing in phase I in solid tumors with the objective to determine maximum tolerated dose and identify a phase II dose."

Acute Myelogenous Leukemia • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • Oncology • Prostate Cancer • Solid Tumor • NRAS • TP53

A Phase I study of PMR-116 in Patients with Advanced Malignancies (ANZCTR) - P1 | N=54 | Terminated | Sponsor: Pimera Australia Pty Ltd | Recruiting ➔ Terminated

Metastases • Trial termination • Oncology • Solid Tumor

RNA Polymerase I inhibitors for cancer therapy (LCC 2023) - "To address the need for improved Pol I inhibitors with minimal off-target effects we collaborated with Pimera Inc to develop a selective 2nd-generation Pol I inhibitor, PMR-116. We show that combinatorial therapy with CX-5461 and both Flavopiridol and Dinaciclib have a synergistic effect in vitro and significantly increase the survival of acute myeloid leukaemia (AML) models in vivo. Our data indicates that inhibition of both Pol I (by CX-5461) and Pol II (by CDK9 inhibitors) can be used in as a therapy to extend survival and reduce acquired resistance."

Acute Myelogenous Leukemia • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Hepatocellular Cancer • Hepatology • Leukemia • Oncology • Prostate Cancer • Solid Tumor • BRCA1 • BRCA2

PMR-116, a novel inhibitor of ribosome biogenesis with antitumor activity in preclinical models of prostate cancer (AACR 2022) - "PMR-116 treatment decreased tumour volume in all PDX tested including complete response in a line in which tumour volume decreased by ~90% compared to baseline.We believe this new RNA Pol I inhibitor shows promising results in a wide range of preclinical models and may exert higher efficacy in tumours expressing high levels of MYC. PMR-116 is currently in Phase I dose escalation trial in patient with solid tumours (ACTRN12620001146987)."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • EIF4EBP1 • PTEN

Pimera Therapeutics Announces Oral Presentation on PMR-116 at the American Association for Cancer Research (AACR) Annual Meeting 2022 (PRNewswire) - "Pimera Therapeutics... announced today that an oral presentation on PMR-116 will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held in New Orleans, LA, April 8-13, 2022."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Pimera Therapeutics Awarded Grant by US Department of Defense to Evaluate PMR-116, a Novel Inhibitor of RNA Polymerase I (Pol I) Transcription, in Patients with Prostate Cancer (PRNewswire) - "Pimera Therapeutics, Inc...announced...that the Company and its collaborators Dr. Luc Furic, Head, Translational Prostate Cancer Research at Peter MacCallum Cancer Centre and Professor Ross Hannan, Centenary Chair in Cancer Research and Head of the ACRF Department of Cancer Biology and Therapeutics, Associate Dean Research (Biomedical and Translational) at Australian National University, have been awarded a Prostate Cancer Research Program (PCRP) grant from the Department of Defense to advance its lead program PMR-116 to the clinic for prostate cancer....The grant award, which totals more than $1 million, will support efficacy studies of PMR-116 in patient-derived models, identification of novel combination therapies, and identification of biomarkers of response from the ongoing Phase 1 study of PMR-116."

Financing • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor